PATENT CLAIM ANALYSIS

Application Number: 15952516
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "006800"]

Abstract:
Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a β-Klotho-binding protein, an FGFR1-binding protein, a β-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.

Claim (Index 18):
The method of  claim 1 , wherein the mammal is a cat or dog.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 91.0
- Lexical Diversity: 1.5614
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14520178', '14176992', '15283862', '15896469', '13641041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.810038263007604
- 35 USC 102 Novelty (BERT): 0.6174208434427678
- Combined Prediction Score: 0.7907765210511203
- Mean Citation Score: 436.727788
- Max Citation Score: 675.9603
- Similarity Product: 474.39747249237297

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test